Carvykti’s Revenue Increases Over +60% QoQ; JNJ Q2 2023 Earnings Call Summary

On Thursday, July 20, JNJ held its Q2 and H1 2023 earnings call (press release / presentation) highlighting Carvykti’s (BCMA CAR-T) remarkable revenue growth. Below, Celltelligence provides insights on the increase in Carvykti sales, while discussing JNJ / Legend’s ongoing strategies to improve CAR-T manufacturing capacity and analyzing Carvykti’s supply limitations ex-US.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.